Longevity biotechnology's crossover into veterinary medicine offers an intriguing look at how commercial and scientific interests are converging to advance translational therapies.
Key Takeaways
- Rejuvenate Bio closed a $6 million financing round led by VCapital
- Merck Animal Health joined the investment and entered a strategic R&D collaboration
- Collaboration targets gene therapy programs for chronic age-related diseases in companion animals